Stopping biologic therapy for Takayasu arteritis in stable patients
Treatments studied
Part of Heart & circulation, Skin clinical trials.
This study looks at whether it is safe for people with Takayasu arteritis to stop taking their biologic medication (like TNF inhibitors or tocilizumab) if they have been in remission—meaning their disease has been quiet—for a long time. You might join this trial if your condition has been stable for years and you haven't needed steroids lately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Takayasu arteritis by a rheumatologist
- You have been on a biologic drug (such as TNF inhibitors or tocilizumab) for at least 3 years
- Your disease has been quiet (no symptoms, normal blood tests, and stable scans) for the past year
- You have not taken any steroids for at least 6 months
- You can come to the hospital for scheduled check-ups after stopping or reducing your biologic
- You are not pregnant and do not plan to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a personalized treatment plan based on your specific disease markers to standard care, aiming to find which is more effective and safer for active Takayasu's arteritis. It may help researchers learn how to better control inflammation and prevent flares.
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
This trial tests a drug called secukinumab to see if it can help people with severe Takayasu arteritis, a rare disease that causes inflammation in the blood vessels. The drug works by blocking a protein that drives inflammation, which may reduce disease activity and help people lower their steroid dose.
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
This trial tests whether adding pirfenidone (a drug that reduces scarring) to your usual treatment helps limit blood vessel thickening and scarring in Takayasu arteritis. You must still have some signs of active disease despite being on standard therapy.
This study collects medical information from patients diagnosed with Takayasu arteritis, a rare disease affecting large blood vessels. By joining, you help researchers better understand this condition and improve care for future patients.
Hear when a new Takayasu Arteritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.